Blood Advances

The Blood Journals Portfolio is consolidating our X accounts. This account will no longer actively post after July 7, 2025. Follow us @bloodportfolio.

[Blood Advances @BloodAdvances]

🚨📣The Blood Journals Portfolio is consolidating our X accounts. Please follow us at @BloodPortolio. This account will no longer actively post after July 7, 2025.
#BloodPortolio #BloodJournals

[Blood Advances @BloodAdvances]

Subpopulations of donor RBCs with low deformability are selectively cleared within 24 hours of transfusion in a murine model. https://t.co/KK5ObpfpEi #redcellsironanderythropoiesis #transfusionmedicine

[Blood Advances @BloodAdvances]

Anti-PF4/heparin and anti-PF4 antibodies can cooperate to induce platelet activation, thrombocytopenia, and thrombus formation. https://t.co/ohhkQTF2KZ #thrombosisandhemostasis

[Blood Advances @BloodAdvances]

High-risk RUNX1 and STAG2, but not low-risk TET2, mutations selectively expand different compartments of SF3B1-mutant primitive HSPCs. https://t.co/UGDvJUJzKk #myeloidneoplasia

[Blood Advances @BloodAdvances]

AhR ligand treatment ameliorates CNS GVHD by reducing NF-κB signaling in microglia thereby providing a novel therapeutic target. https://t.co/CLkqiPkjXu #transplantation #immunobiologyandimmunotherapy

[Blood Advances @BloodAdvances]

Exposure of endothelial cells to serum or IgG from patients with VITT induced TF expression and thromboinflammation. https://t.co/xJxafPD1B8 #thrombosisandhemostasis #vascularbiology

[Blood Advances @BloodAdvances]

ED visits by people with SCD declined after the PDMP started, especially after the PDMP mandate began. https://t.co/0LmbSSLx2R #healthservicesandoutcomes #redcellsironanderythropoiesis

[Blood Advances @BloodAdvances]

RHOA G17V enhances CD3/CD28-induced NFAT transcriptional activity by binding p300 and enhancing its histone acetyltransferase activity. https://t.co/L1xLSr8dHV #lymphoidneoplasia

[Blood Advances @BloodAdvances]

miR-150-5p acts as tumor suppressor by repressing the lymphomagenic-driver E2F3, leading to cell cycle disruption in PBL. https://t.co/NufzoUyrYS #lymphoidneoplasia

[Blood Advances @BloodAdvances]

A progression signature was found that commonly increased in expression during the progression from patch to plaque and from plaque to tumor. https://t.co/5hPEp6AgLr #immunobiologyandimmunotherapy #lymphoidneoplasia

[Blood Advances @BloodAdvances]

Zanubrutinib demonstrated reduced risk of progression/death compared to ibrutinib, acalabrutinib, and bendamustine or idelalisib+rituximab. https://t.co/ojHOlqWzT3 #lymphoidneoplasia

[Blood Advances @BloodAdvances]

CD19.CAR+EVs represent a new dynamic biomarker of CAR T-cell activity and contribute to the direct killing of cancer targets. https://t.co/e5S9fjdWet #genetherapy #immunobiologyandimmunotherapy #lymphoidneoplasia

[Blood Advances @BloodAdvances]

PEA exerts neuroprotective effects in central nervous system and peripheral neurons and reduces inflammation. https://t.co/LCm8YCcclR #redcellsironanderythropoiesis

[Blood Advances @BloodAdvances]

The bedside SaO2/FiO2 ratio is an inexpensive biomarker to assess ACS severity and guide transfer to the ICU. https://t.co/drsOkvlxBl #healthservicesandoutcomes #redcellsironanderythropoiesis

[Blood Advances @BloodAdvances]

Strongest predictor of improvement was baseline score, reinforcing importance of early initiation of treatment to reduce risk of decline. https://t.co/Y56ZKEchj7 #clinicaltrialsandobservations #globaladvances #redcellsironanderythropoiesis

[Blood Advances @BloodAdvances]

Participants with hemophilia B in the 101HEMB01/101HEMB02 studies failed to achieve plasma FIX levels of 20 IU/dL with DTX101 treatment. https://t.co/6rNHMe4SRd #clinicaltrialsandobservations #genetherapy

[Blood Advances @BloodAdvances]

The prognostic role of early metabolic response is independent from the type of induction therapy and maintenance therapy. https://t.co/dcTpxv5BZe #clinicaltrialsandobservations #lymphoidneoplasia

[Blood Advances @BloodAdvances]

A comparison between interventions that will be sought by providers and patients undergoing intervention requires uniform assessments that evaluate disease- and intervention-related effects for informed decision-making. https://t.co/rHz6rYR4P5 #healthservicesandoutcomes

[Blood Advances @BloodAdvances]

T-cell receptor therapies are a promising modality for the treatment of cancers, with significant efforts being directed toward acute myeloid leukemia, a particularly challenging disease. https://t.co/rfI9oElgFi #immunobiologyandimmunotherapy #myeloidneoplasia

[Blood Advances @BloodAdvances]

Venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism, represents a complex pathological process extending far beyond inflammatory mechanisms. https://t.co/R1BDWuLesK #thrombosisandhemostasis

[Blood Advances @BloodAdvances]

Congenital or hereditary thrombotic thrombocytopenic purpura is a rare autosomal recessive disease caused by biallelic severe defects in the ADAMTS13 gene, either homozygous or compound heterozygous. https://t.co/IgDYKqs2O8 #thrombosisandhemostasis